
Jean-Michel Sallenave

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6508905/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	IL-6-elafin genetically modified macrophages as a lung immunotherapeutic strategy against Pseudomonas aeruginosa infections. Molecular Therapy, 2022, 30, 355-369.	8.2	7
2	Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?. Frontiers in Immunology, 2020, 11, 1229.	4.8	105
3	Influenza A Virus Pre-Infection Exacerbates Pseudomonas aeruginosa-Mediated Lung Damage Through Increased MMP-9 Expression, Decreased Elafin Production and Tissue Resilience. Frontiers in Immunology, 2020, 11, 117.	4.8	17
4	Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity. Biomaterials, 2019, 217, 119308.	11.4	53
5	Silver Nanoparticles Impair Retinoic Acid-Inducible Gene I-Mediated Mitochondrial Antiviral Immunity by Blocking the Autophagic Flux in Lung Epithelial Cells. ACS Nano, 2018, 12, 1188-1202.	14.6	56
6	Human airway trypsinâ€ i ike protease exerts potent, antifibrotic action in pulmonary fibrosis. FASEB Journal, 2018, 32, 1250-1264.	0.5	6
7	Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator–IL-6–antimicrobial–repair pathway. Thorax, 2018, 73, 49-61.	5.6	74
8	Pseudomonas aeruginosa LasB Subverts Alveolar Macrophage Activity by Interfering With Bacterial Killing Through Downregulation of Innate Immune Defense, Reactive Oxygen Species Generation, and Complement Activation. Frontiers in Immunology, 2018, 9, 1675.	4.8	54
9	Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. Cell, 2017, 168, 1086-1100.e10.	28.9	420
10	The antimicrobial molecule trappin-2/elafin has anti-parasitic properties and is protective in vivo in a murine model of cerebral malaria. Scientific Reports, 2017, 7, 42243.	3.3	18
11	Human airway trypsin-like protease, a serine protease involved in respiratory diseases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L657-L668.	2.9	32
12	Editorial: Neutrophil elastase and the lung: is it degradation, repair, emphysema, or fibrosis? What tilts it left or right?. Journal of Leukocyte Biology, 2015, 98, 137-139.	3.3	3
13	Cyclosporine Does Not Prevent Microvascular Loss in Transplantation but Can Synergize With a Neutrophil Elastase Inhibitor, Elafin, to Maintain Graft Perfusion During Acute Rejection. American Journal of Transplantation, 2015, 15, 1768-1781.	4.7	14
14	Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microbial Cell Factories, 2015, 14, 26.	4.0	103
15	Acute exposure to silica nanoparticles enhances mortality and increases lung permeability in a mouse model of Pseudomonas aeruginosa pneumonia. Particle and Fibre Toxicology, 2015, 12, 1.	6.2	57
16	Sheep Lung Segmental Delivery Strategy Demonstrates Adenovirus Priming of Local Lung Responses to Bacterial LPS and the Role of Elafin as a Response Modulator. PLoS ONE, 2014, 9, e107590.	2.5	3
17	Phagocytic and signaling innate immune receptors: are they dysregulated in cystic fibrosis in the fight against Pseudomonas aeruginosa?. International Journal of Biochemistry and Cell Biology, 2014, 52, 103-107.	2.8	13
18	Cystic fibrosis, a multi-systemic mucosal disease: 25 years after the discovery of CFTR. International Journal of Biochemistry and Cell Biology, 2014, 52, 2-4.	2.8	7

#	Article	IF	CITATIONS
19	Internalization of SiO2 nanoparticles by alveolar macrophages and lung epithelial cells and its modulation by the lung surfactant substitute CurosurfÁ®. Environmental Science and Pollution Research, 2013, 20, 2761-2770.	5.3	36
20	Antiviral Activity of Trappin-2 and Elafin <i>In Vitro</i> and <i>In Vivo</i> against Genital Herpes. Journal of Virology, 2013, 87, 7526-7538.	3.4	28
21	Antiâ€ŧumor effect of SLPI on mammary but not colon tumor growth. Journal of Cellular Physiology, 2013, 228, 469-475.	4.1	9
22	Neutrophil Elastase Degrades Cystic Fibrosis Transmembrane Conductance Regulator via Calpains and Disables Channel Function <i>In Vitro</i> and <i>In Vivo</i> American Journal of Respiratory and Critical Care Medicine, 2013, 187, 170-179.	5.6	97
23	WAPing Out Pathogens and Disease in the Mucosa: Roles for SLPI and Trappin-2. , 2013, , 141-166.		Ο
24	Ventilator-Associated Pneumonia Is Characterized by Excessive Release of Neutrophil Proteases in the Lung. Chest, 2012, 142, 1425-1432.	0.8	588
25	Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16528-16533.	7.1	166
26	The WAP protein Trappin-2/Elafin: A handyman in the regulation of inflammatory and immune responses. International Journal of Biochemistry and Cell Biology, 2012, 44, 1377-1380.	2.8	40
27	Endogenous antimicrobial molecules: Important mediators in alveolar macrophage–epithelial cell interaction in the lung. Revue Francaise D'allergologie, 2012, 52, 141-144.	0.2	0
28	Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis. Science Translational Medicine, 2012, 4, 158ra144.	12.4	198
29	Influenza A Induces the Major Secreted Airway Mucin MUC5AC in a Protease–EGFR–Extracellular Regulated Kinase–Sp1–Dependent Pathway. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 149-157.	2.9	76
30	Toll-like receptor 5 (TLR5), IL-1β secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killing. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1619-1624.	7.1	108
31	Trappin-2/Elafin Modulate Innate Immune Responses of Human Endometrial Epithelial Cells to Polylâ^¶C. PLoS ONE, 2012, 7, e35866.	2.5	14
32	Modifying the Protease, Antiprotease Pattern by Elafin Overexpression Protects Mice From Colitis. Gastroenterology, 2011, 140, 1272-1282.	1.3	102
33	WAP domain proteins as modulators of mucosal immunity. Biochemical Society Transactions, 2011, 39, 1409-1415.	3.4	49
34	CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. British Journal of Dermatology, 2011, 164, 720-728.	1.5	41
35	Serine leucocyte proteinase inhibitor-treated monocyte inhibits human CD4+ lymphocyte proliferation. Immunology, 2011, 133, 434-441.	4.4	21
36	Deletion of serpina1a, a murine α ₁ -antitrypsin ortholog, results in embryonic lethality. Experimental Lung Research, 2011, 37, 291-300.	1.2	24

JEAN-MICHEL SALLENAVE

#	Article	IF	CITATIONS
37	Transcriptomic Analysis of Host Immune and Cell Death Responses Associated with the Influenza A Virus PB1-F2 Protein. PLoS Pathogens, 2011, 7, e1002202.	4.7	62
38	Serine and Cysteine Proteases and Their Inhibitors as Antimicrobial Agents and Immune Modulators. , 2011, , 27-50.		4
39	An additive interaction between the NFκB and estrogen receptor signalling pathways in human endometrial epithelial cells. Human Reproduction, 2010, 25, 510-518.	0.9	47
40	Secretory Leukocyte Protease Inhibitor and Elafin/Trappin-2. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 635-643.	2.9	109
41	Diagnostic importance of pulmonary interleukin-1Â and interleukin-8 in ventilator-associated pneumonia. Thorax, 2010, 65, 201-207.	5.6	95
42	Lung protease/anti-protease network and modulation of mucus production and surfactant activity. Biochimie, 2010, 92, 1608-1617.	2.6	36
43	Intranasal Mucosal Boosting with an Adenovirus-Vectored Vaccine Markedly Enhances the Protection of BCG-Primed Guinea Pigs against Pulmonary Tuberculosis. PLoS ONE, 2009, 4, e5856.	2.5	104
44	C5a Mediates Peripheral Blood Neutrophil Dysfunction in Critically III Patients. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 19-28.	5.6	103
45	IL-33 Enhances Lipopolysaccharide-Induced Inflammatory Cytokine Production from Mouse Macrophages by Regulating Lipopolysaccharide Receptor Complex. Journal of Immunology, 2009, 183, 1446-1455.	0.8	142
46	Trappin-2 Promotes Early Clearance of Pseudomonas aeruginosa through CD14-Dependent Macrophage Activation and Neutrophil Recruitment. American Journal of Pathology, 2009, 174, 1338-1346.	3.8	37
47	Neutrophil Elastase (NE) and NE Inhibitors: Canonical and Noncanonical Functions in Lung Chronic Inflammatory Diseases (Cystic Fibrosis and Chronic Obstructive Pulmonary Disease). Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 125-144.	1.4	56
48	Human neutrophil elastase: Mediator and therapeutic target in atherosclerosis. International Journal of Biochemistry and Cell Biology, 2008, 40, 1095-1100.	2.8	72
49	Proteases and antiproteases in development, homeostasis and disease: The old, the new, and the unknown…. International Journal of Biochemistry and Cell Biology, 2008, 40, 1066-1067.	2.8	5
50	Altered secretory leukocyte protease inhibitor expression in the uterine decidua of tubal compared with intrauterine pregnancy. Human Reproduction, 2008, 23, 1485-1490.	0.9	9
51	Aspergillus fumigatus-induced Interleukin-8 Synthesis by Respiratory Epithelial Cells Is Controlled by the Phosphatidylinositol 3-Kinase, p38 MAPK, and ERK1/2 Pathways and Not by the Toll-like Receptor-MyD88 Pathway. Journal of Biological Chemistry, 2008, 283, 30513-30521.	3.4	90
52	Neutrophil Elastase (NE) and NE Inhibitors: Canonical and Noncanonical Functions in Lung Chronic Inflammatory Diseases (Cystic Fibrosis and Chronic Obstructive Pulmonary Disease). Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
53	Role of Toll-like receptors in lung innate defense against invasive aspergillosis. Distinct impact in immunocompetent and immunocompromized hosts. Clinical Immunology, 2007, 124, 238-243.	3.2	47
54	Expression of Natural Antimicrobials by Human Placenta and Fetal Membranes. Placenta, 2007, 28, 161-169.	1.5	183

#	Article	IF	CITATIONS
55	Innate Immune Defences in the Human Uterus during Pregnancy. Placenta, 2007, 28, 1099-1106.	1.5	109
56	SLPI and elafin: one glove, many fingers. Clinical Science, 2006, 110, 21-35.	4.3	246
57	Elastin Fragments Induce IL-1β Upregulation via NF-κB Pathway in Melanoma Cells. Journal of Investigative Dermatology, 2006, 126, 1860-1868.	0.7	35
58	Inflammatory Lung Secretions Inhibit Dendritic Cell Maturation and Function via Neutrophil Elastase. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1189-1198.	5.6	71
59	The Antimicrobial/Elastase Inhibitor Elafin Regulates Lung Dendritic Cells and Adaptive Immunity. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 634-642.	2.9	44
60	Local lung responses following endobronchial elastase and lipopolysaccharide instillation in sheep. International Journal of COPD, 2006, 1, 189-199.	2.3	3
61	Characterization of the ovine ortholog of secretory leukoprotease inhibitor. Mammalian Genome, 2005, 16, 621-630.	2.2	13
62	Antimicrobial Activity of Murine Lung Cells against <i>Staphylococcus aureus</i> Is Increased In Vitro and In Vivo after Elafin Gene Transfer. Infection and Immunity, 2005, 73, 3609-3617.	2.2	36
63	The Antimicrobial Antiproteinase Elafin Binds to Lipopolysaccharide and Modulates Macrophage Responses. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 443-452.	2.9	58
64	Trappin ovine molecule (TOM), the ovine ortholog of elafin, is an acute phase reactant in the lung. Physiological Genomics, 2004, 19, 11-21.	2.3	14
65	Adenoviral Gene Delivery of Elafin and Secretory Leukocyte Protease Inhibitor Attenuates NF-κB-Dependent Inflammatory Responses of Human Endothelial Cells and Macrophages to Atherogenic Stimuli. Journal of Immunology, 2004, 172, 4535-4544.	0.8	136
66	Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastaseâ€mediated impairment of apoptotic cell recognition. FEBS Letters, 2004, 574, 80-84.	2.8	34
67	Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics. Current Pharmaceutical Design, 2004, 10, 2891-2905.	1.9	64
68	Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochemical and Biophysical Research Communications, 2003, 310, 594-599.	2.1	63
69	Annexin A1 processing is associated with caspase-dependent apoptosis in BZR cells. FEBS Letters, 2003, 546, 195-202.	2.8	58
70	Regulation of Pulmonary and Systemic Bacterial Lipopolysaccharide Responses in Transgenic Mice Expressing Human Elafin. Infection and Immunity, 2003, 71, 3766-3774.	2.2	54
71	Elafin in Human Endometrium: An Antiprotease and Antimicrobial Molecule Expressed during Menstruation. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4426-4431.	3.6	81
72	Neutrophil DNA Contributes to the Antielastase Barrier during Acute Lung Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 746-753.	2.9	14

#	Article	IF	CITATIONS
73	House Dust Mite Der p 1 Downregulates Defenses of the Lung by Inactivating Elastase Inhibitors. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 381-389.	2.9	83
74	Cytokines in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Current Pharmaceutical Design, 2003, 9, 25-38.	1.9	28
75	Antimicrobial activity of antiproteinases. Biochemical Society Transactions, 2002, 30, 111-115.	3.4	116
76	Regulation of Adenovirus-Mediated Elafin Transgene Expression by Bacterial Lipopolysaccharide. Human Gene Therapy, 2001, 12, 1395-1406.	2.7	46
77	Adenoviral Augmentation of Elafin Protects the Lung Against Acute Injury Mediated by Activated Neutrophils and Bacterial Infection. Journal of Immunology, 2001, 167, 1778-1786.	0.8	86
78	The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific) Tj ETQq0 0 0 rgBT /Overlock 10 Respiratory Research, 2000, 1, 87-92.	Tf 50 547 3.6	Td (inhibitor/ 123
79	Elafin (elastaseâ€specific inhibitor) has antiâ€microbial activity against Gramâ€positive and Gramâ€negative respiratory pathogens. FEBS Letters, 1999, 452, 309-313.	2.8	177
80	Human neutrophil elastase regulates the expression and secretion of elafin (elastaseâ€specific) Tj ETQq0 0 0 rgB	T /Oyerloc 2.8	k 19 Tf 50 46
81	Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. European Respiratory Journal, 1999, 13, 1029-1036.	6.7	42
82	Elastase Inhibitors in the Lung: Expression and Functional Relationships. , 1999, , 69-94.		2
83	Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters. Gene Therapy, 1998, 5, 352-360.	4.5	48
84	Gene therapy for lung inflammatory diseases: not so far away?. Thorax, 1997, 52, 742-744.	5.6	14
85	In Vivo Adenovirus-Mediated Expression of Human Pre-Elafin, a Potent Neutrophil Elastase Inhibitor. Chest, 1997, 111, 128S-129S.	0.8	6
86	Oncostatin M, but Not Interleukin-6 or Leukemia Inhibitory Factor, Stimulates Expression of Alpha1-Proteinase Inhibitor in A549 Human Alveolar Epithelial Cells. Journal of Interferon and Cytokine Research, 1997, 17, 337-346.	1.2	35
87	Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. Journal of Leukocyte Biology, 1997, 61, 695-702.	3.3	130
88	Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung American Journal of Respiratory and Critical Care Medicine, 1996, 154, 1092-1098.	5.6	47
89	Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. Journal of Leukocyte Biology, 1996, 59, 481-488.	3.3	82
90	Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes American Journal of Respiratory Cell and Molecular Biology, 1994, 11, 733-741.	2.9	285

#	Article	IF	CITATIONS
91	Characterization and Gene Sequence of the Precursor of Elafin, an Elastase-specific Inhibitor in Bronchial Secretions. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 439-445.	2.9	80
92	Secretion of Mucus Proteinase Inhibitor and Elafin by Clara Cell and Type II Pneumocyte Cell Lines. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 126-133.	2.9	68
93	Isolation of Elafin and Elastase-Specific Inhibitor (ESI) from Bronchial Secretions. Evidence of Sequence Homology and Immunological Cross-Reactivity. Biological Chemistry Hoppe-Seyler, 1992, 373, 27-34.	1.4	59
94	Subunit structure of calgranulins A and B obtained from sputum, plasma, granulocytes and cultured epithelial cells. BBA - Proteins and Proteomics, 1992, 1120, 215-222.	2.1	14
95	Purifkation and Characterization of Elastase-Specific Inhibitor. Sequence Homology with Mucus Proteinase Inhibitor. Biological Chemistry Hoppe-Seyler, 1991, 372, 13-22.	1.4	93
96	Evidence of an α2-macroglobulin-like molecule in plasma ofSalamandra salamandraStructural and functional similarity with human α2-macroglobulin. FEBS Letters, 1987, 219, 37-39.	2.8	3